HyEnergy Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

HyEnergy heeft een totaal eigen vermogen van PLN2.8M en een totale schuld van PLN30.0K, wat de schuld-eigenvermogensverhouding op 1.1% brengt. De totale activa en totale passiva bedragen respectievelijk PLN5.5M en PLN2.7M.

Belangrijke informatie

1.1%

Verhouding schuld/eigen vermogen

zł30.00k

Schuld

Rente dekkingsratio	n/a
Contant	zł1.59m
Aandelen	zł2.81m
Totaal verplichtingen	zł2.69m
Totaal activa	zł5.50m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( PLN3.0M ) IGN } overtreffen de korte termijn passiva ( PLN2.5M ).

Langlopende schulden: De kortetermijnactiva IGN ( PLN3.0M ) overtreffen de langetermijnschulden ( PLN203.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IGN heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van IGN is de afgelopen 5 jaar gedaald van 24.2% naar 1.1%.

Schuldendekking: De operationele kasstroom van IGN is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van IGN op haar schulden goed worden gedekt door EBIT.

HyEnergy Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

New major risk - Shareholder dilution

Inno-Gene S.A. announced that it expects to receive PLN 14.25 million in funding

Second quarter 2024 earnings released

Inno-Gene S.A., Annual General Meeting, Aug 13, 2024

Inno-Gene S.A. to Report Q4, 2023 Results on Jun 30, 2024

First quarter 2024 earnings released

Full year 2023 earnings released: zł0.26 loss per share (vs zł0.35 loss in FY 2022)

Inno-Gene S.A. to Report Q2, 2024 Results on Aug 09, 2024

Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding

New major risk - Revenue and earnings growth

Inno-Gene S.A., Annual General Meeting, Sep 27, 2023

Inno-Gene S.A. to Report Fiscal Year 2022 Results on Aug 31, 2023

Inno-Gene S.A. to Report Fiscal Year 2022 Results on Jul 31, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: EPS: zł0.058 (vs zł1.08 in FY 2021)

Inno-Gene S.A. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Inno-Gene S.A., Annual General Meeting, Jun 30, 2022

Inno-Gene S.A. (WSE:IGN) acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million.

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inno-Gene S.A. to Report Q3, 2022 Results on Nov 14, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock

Investor sentiment deteriorated over the past week

Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?

Second quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released

We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide

Full year 2020 earnings released: EPS zł0.84 (vs zł0.029 loss in FY 2019)

New 90-day low: zł19.70

Inno-Gene S.A. to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: zł21.00

President of the Management Board recently sold zł3.2m worth of stock

New 90-day high: zł30.00

New 90-day low - zł10.00

Inno-Gene S.A. (WSE:IGN) acquired unknown stake in INNGEN SA for PLN 0.01 million.

First half earnings released

New 90-day high - zł19.25

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven